United States Últimas notícias

Protolabs (NYSE:PRLB) reported record second-quarter 2026 revenue of $149.3 million, up 10.6% year over year, supported by growth in CNC machining and injection molding services.

WisdomTree (NYSE:WT) reported second-quarter 2026 net income of $44.3 million, or $48.1 million on an adjusted basis, as assets under management increased to $162.9 billion.

Ares Management (NYSE:ARES) announced its second-quarter 2026 financial results, posting a GAAP net income attributable to the company of $150.6 million, or $0.49 per share.

Linde (NASDAQ:LIN) reported second-quarter 2026 sales of $9.3 billion, up 9% year over year, with adjusted earnings per share increasing as the company reported higher operating performance.

Apple (NASDAQ:AAPL) shares fell 7.3% before the market open on Friday after the company warned that supply constraints could limit growth, raising concerns about future product availability.

Magna (NYSE:MGA) reported second-quarter 2026 sales of $11 billion, up 3% year over year, outperforming a 2% decline in global light vehicle production.

Portland General Electric (NYSE:POR) reported second-quarter 2026 GAAP net income of $68 million, or $0.59 per diluted share, compared with $62 million, or $0.56 per share, in the prior-year quarter.

Compañía de Minas Buenaventura (NYSE:BVN) reported second-quarter 2026 net income of $260.6 million, compared with $98.2 million in the prior-year quarter, as gold production increased during the period.

Kyivstar Group (NASDAQ:KYIV) reported second-quarter 2026 revenue of $339 million, up 19.3% year over year, as digital services growth contributed to higher group performance.

VEON (NASDAQ:VEON) reported second-quarter 2026 revenue of $1.27 billion, up 17% year over year, as digital services growth supported overall performance.

Datroway (datopotamab deruxtecan), developed by Daiichi Sankyo and AstraZeneca (NYSE:AZN), received European Union approval as a monotherapy treatment for adults with unresectable or metastatic triple negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

Sony Group (NYSE:SONY) reported fiscal first-quarter 2026 net profit of ¥342.2 billion, up 32% year over year, as revenue increased across several business areas.